

# BioCentury Part II

THE BERNSTEIN REPORT ON BIOBUSINESS™

Article Reprint • Page 1 of 1

## COMPANY NEWS/Deals, Sales & Marketing, Other News, Management Tracks

### SALES & MARKETING

**Caris Life Sciences Inc.**, Irving, Texas

**Signal Genetics LLC**, New York, N.Y.

Business: Diagnostic

Caris will offer Signal's Myeloma Prognostic Risk Signature (MyPRS) gene expression profile test to community-based hematologists and medical oncologists in the U.S. MyPRS analyzes and applies an algorithm to a defined number of relevant genes to determine the gene expression profile associated with the patient's condition. The analysis will be performed at Signal Genetics' CLIA-certified laboratory in Little Rock, Ark. Further terms were not disclosed.

**BioCentury®**  
THE BERNSTEIN REPORT ON BIOBUSINESS

PO Box 1246  
San Carlos CA 94070-1246  
Voice: 650-595-5333  
Fax: 650-595-5589  
[www.biocentury.com](http://www.biocentury.com)

**DAVID FLORES**  
President & CEO

**KAREN BERNSTEIN, Ph.D.**  
Chairman & Editor-in-Chief

BioCentury®, The BioCentury 100, and The Clear Route are trademarks of BioCENTURY PUBLICATIONS INC. All contents © Copyright 2011, BioCENTURY PUBLICATIONS INC. ALL RIGHTS RESERVED. No part of this publication may be reproduced, photocopied or reproduced in any form, retransmitted, or stored in a retrieval system without prior written consent of the publisher.

The contents of this publication are gathered from sources believed to be reliable, but in any case are not warranted by the publisher for a particular use or purpose. Also, the content and opinions herein may change without notice and do not constitute investment advice.